Neuphoria Therapeutics (NEUP) Revenue & Revenue Breakdown

Neuphoria Therapeutics Revenue Highlights

Main Segment (Y)

Licences

Main Geography (Y)

Licences

Neuphoria Therapeutics Revenue by Period

Neuphoria Therapeutics Revenue by Year

Date	Revenue	Change
2024-06-30	-	-100.00%
2023-06-29	$20.00K	-92.31%
2022-06-30	$260.00K	100.00%
2021-06-30	-	-100.00%
2020-06-30	$50.00K	-98.69%
2019-06-29	$3.82M	-56.56%
2018-06-30	$8.79M	-57.70%
2017-06-30	$20.79M	45.11%
2016-06-30	$14.33M	116.11%
2015-06-30	$6.63M	-85.21%
2014-06-30	$44.81M	2637.18%
2013-06-30	$1.64M	45.39%
2012-06-30	$1.13M	-64.62%
2011-06-30	$3.18M	6.34%
2010-06-30	$2.99M	-17.09%
2009-06-30	$3.61M	220.65%
2008-06-30	$1.13M	38.04%
2007-06-30	$815.72K	25.04%
2006-06-30	$652.38K	120.73%
2005-06-30	$295.55K	100.00%
2004-06-30	-	-100.00%
2003-06-30	$1.03M	-36.20%
2002-06-30	$1.61M	169.05%
2001-06-30	$599.00K	100.00%
2000-06-30	-	100.00%
1999-06-30	-	-

Neuphoria Therapeutics generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Neuphoria Therapeutics Revenue by Quarter

Date	Revenue	Change
2025-09-30	-	-100.00%
2025-06-30	$-15.66M	-204.42%
2025-03-31	$15.00M	2163.42%
2024-12-31	$662.72K	100.00%
2024-09-30	-	100.00%
2024-06-30	-	100.00%
2024-03-31	-	100.00%
2023-12-31	-	100.00%
2023-09-30	-	-100.00%
2023-06-29	$20.00K	-88.42%
2023-03-31	$172.76K	100.00%
2022-12-30	-	-100.00%
2022-09-30	$42.46K	-98.96%
2022-06-30	$4.06M	6065.76%
2022-03-31	$65.91K	-46.44%
2021-12-31	$123.06K	86.71%
2021-09-30	$65.91K	100.00%
2021-06-29	-	-100.00%
2021-03-31	$11.67K	-97.50%
2020-12-31	$466.51K	3899.07%
2020-09-30	$11.67K	-87.88%
2020-06-30	$96.25K	725.05%
2020-03-31	$11.67K	-99.02%
2019-12-31	$1.20M	25.13%
2019-09-30	$956.11K	-15.62%
2019-06-30	$1.13M	18.52%
2019-03-31	$956.11K	1.89%
2018-12-31	$938.36K	-
2018-09-30	$938.36K	-
2018-06-30	$938.36K	-
2018-03-31	$938.36K	-30.18%
2017-12-31	$1.34M	-
2017-09-30	$1.34M	-
2017-06-30	$1.34M	-
2017-03-31	$1.34M	-23.02%
2016-12-31	$1.75M	-
2016-09-30	$1.75M	-
2016-06-30	$1.75M	-
2016-03-31	$1.75M	5.34%
2015-12-31	$1.66M	-
2015-09-30	$1.66M	-
2015-06-30	$1.66M	-
2015-03-31	$1.66M	-65.37%
2014-12-31	$4.79M	-
2014-09-30	$4.79M	-
2014-06-30	$4.79M	-
2014-03-31	$4.79M	1069.19%
2013-12-31	$409.30K	-
2013-09-30	$409.30K	-
2013-06-30	$409.30K	-
2013-03-31	$409.30K	45.39%
2012-12-31	$281.53K	-
2012-09-30	$281.53K	-
2012-06-30	$281.53K	-
2012-03-31	$281.53K	-64.62%
2011-12-31	$795.79K	-
2011-09-30	$795.79K	-
2011-06-30	$795.79K	-
2011-03-31	$795.79K	6.34%
2010-12-31	$748.33K	-
2010-09-30	$748.33K	-
2010-06-30	$748.33K	-
2010-03-31	$748.33K	-17.09%
2009-12-31	$902.62K	-
2009-09-30	$902.62K	-
2009-06-30	$902.62K	-
2009-03-31	$902.62K	220.65%
2008-12-31	$281.50K	-
2008-09-30	$281.50K	-
2008-06-30	$281.50K	-
2008-03-31	$281.50K	-

Neuphoria Therapeutics generated - in revenue during Q1 2026, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Neuphoria Therapeutics Revenue Breakdown

Neuphoria Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Jun 22
Licences	$263.63K

Neuphoria Therapeutics's latest annual revenue breakdown by segment (product or service), as of Jun 22: Licences (100.00%).

Neuphoria Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Jun 22
Licences	$263.63K

Neuphoria Therapeutics's latest annual revenue breakdown by geography, as of Jun 22: Licences (100.00%).

Neuphoria Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
LUCY	Innovative Eyewear	$1.64B	$579.23K
LFWD	Lifeward	$25.66M	$6.20M
BMRA	Biomerica	$5.42M	$1.38M
PTHL	Pheton Ltd Class A Ordinary Shares	$448.20K	$118.85K
APRE	Aprea Therapeutics	-	$118.11K
ALZN	Alzamend Neuro	-	-
NEUP	Neuphoria Therapeutics	-	-
IINN	Inspira Technologies Oxy B.H.N.	-	-
BCDA	BioCardia	-	-

NEUP Revenue FAQ

What is Neuphoria Therapeutics’s yearly revenue?

Neuphoria Therapeutics's yearly revenue for 2024 was $0, representing a decrease of -100.00% compared to 2023. The company's yearly revenue for 2023 was $20K, representing a decrease of -92.31% compared to 2022. NEUP's yearly revenue for 2022 was $260K, representing an increase of 100.00% compared to 2021.

What is Neuphoria Therapeutics’s quarterly revenue?

Neuphoria Therapeutics's quarterly revenue for Q1 2026 was $0, a -100.00% decrease from the previous quarter (Q4 2025), and a 0% increase year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $-15.663M, a -204.42% decrease from the previous quarter (Q3 2025), and a 0% increase year-over-year (Q4 2024). NEUP's quarterly revenue for Q3 2025 was $15M, a 2163.42% increase from the previous quarter (Q2 2025), and a 0% increase year-over-year (Q3 2024).

What is Neuphoria Therapeutics’s revenue growth rate?

Neuphoria Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -100.00%, and for the last 5 years (2020-2024) was -100.00%.

What are Neuphoria Therapeutics’s revenue streams?

Neuphoria Therapeutics's revenue streams in n 22 are Licences

What is Neuphoria Therapeutics’s main source of revenue?

For the fiscal year ending Jun 22, the largest source of revenue of Neuphoria Therapeutics was Licences. This segment made a revenue of $263.63K, representing 100.00% of the company's total revenue.